Tolerability of Sodium-Glucose Co-transporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Retrospective Cohort Study.

Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an emerging treatment for type 2 diabetes mellitus (T2DM). The effect and tolerability of SGLT2 inhibitors in patients with T2DM, especially related risk factors and susceptible populations, are an area of ongoing research. Aim The aim of this study was to evaluate the tolerability of SGLT2 inhibitors, particularly the risk associated with urogenital infection, in patients with T2DM.

Recurrence Rate in a Patient Treated with Colon Resection Followed by Chemotherapy in Comparison to a Patient Treated with Colon Resection without Chemotherapy.

Given that colon cancer is one of the most prevalent cancers worldwide, it is essential to employ strategies to try to reduce its incidence and recurrence rate. Though colon cancer is a sporadic disease in the vast majority of cases, multiple risk factors are linked to this disease, namely, obesity and cigarette smoking. Additionally, not many studies have been done in Saudi Arabia studying the recurrence rate of colon cancer.

Type 2 Diabetic Patients Adherence Towards Their Medications.

Given that type 2 diabetes mellitus (T2DM) has become a common noncommunicable disease that can begin in early life and has a significant effect on the quality of life, it is important to address treatment adherence. While various factors contribute to the development of T2DM, the primary cause is linked to unhealthy eating and lack of physical activity. Adhering to healthy eating and physical exercise is not generally well tolerated by patients with diabetes, and pharmacological treatments are often necessary.